{
    "clinical_study": {
        "@rank": "124519", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Two subcutaneous injections at flow rate 1"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Single subcutaneous injection at flow rate 2"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Single subcutaneous injection at flow rate 3"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Single subcutaneous injection at flow rate 4"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the pharmacokinetics and tolerability of  tralokinumab\n      when delivered at different flow rates to healthy volunteers."
        }, 
        "brief_title": "A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Healthy males and females ages 19-65 years\n\n          -  Body mass index of 19.0-30.0 kg/m2\n\n          -  No clinically significant abnormality\n\n          -  Vital signs, electrocardiogram (ECG), and laboratory parameters within normal range\n\n          -  Negative alcohol and drug screens\n\n          -  Females of childbearing potential who are sexually active with a nonsterilized male\n             partner must use highly effective contraception\n\n          -  Nonsterilized males who are sexually active with a female partner of childbearing\n             potential must use highly effective contraception\n\n        Key Exclusion Criteria:\n\n          -  Concurrent enrollment in another clinical study where the subject is receiving an\n             investigational product\n\n          -  Receipt of any marketed or investigational biologic agent within 4 months or 5\n             half-lives prior to screening, whichever is longer\n\n          -  Receipt of any investigational nonbiologic agent within 3 months or 5 half-lives\n             prior to screening, whichever is longer\n\n          -  Current use of regular pain-modifying, anti-depressant, anxiolytic, or hypnotic\n             medication\n\n          -  History of thrombocytopenia or bleeding disorder or use of anticoagulants\n\n          -  History of any immunodeficiency disorder or use of immunosuppressive medication.\n\n          -  History of a clinically significant infection\n\n          -  History of cancer\n\n          -  Hepatitis B or C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085473", 
            "org_study_id": "D2210C00011"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3", 
                "Cohort 4"
            ], 
            "description": "Subcutaneous Injection", 
            "intervention_name": "Subcutaneous Injection", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68502"
                    }, 
                    "name": "Celerion"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "MedImmune Contact"
        }, 
        "overall_official": {
            "affiliation": "Celerion", 
            "last_name": "Barbara Cook, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the plasma concentration versus time curve (AUC) of tralokinumab", 
            "safety_issue": "No", 
            "time_frame": "Day 1,2,4,6,8,10,15,22,36,57"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pain intensity, measured using 100mm Visual Analogue Scale (VAS)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to 57"
            }, 
            {
                "measure": "Number of injection site reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to 57"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}